1stOncology™: Cancer Intelligence Service – Page 12625 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Y-mAbs to Host R&D Event and Live Webcast on Wednesday, December 11

On December 5, 2019 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported that it will host an R&D event and live webcast featuring several key opinion leaders ("KOLs") to discuss the Company’s advanced antibody-based therapeutic pipeline and recent clinical and corporate developments on Wednesday, December 11, 2019 from 12:00-2:00pm EST in New York City (Press release, Y-mAbs Therapeutics, DEC 5, 2019, View Source [SID1234551972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The event will feature presentations by KOLs Dr. Shakeel Modak, M.D., MRCP, Memorial Sloan Kettering Cancer Center ("MSK"), Dr. Kim Kramer, M.D., MSK, and Dr. Jaume Mora, M.D., Ph.D., SJD Barcelona Children’s Hospital, who will discuss the current treatment landscape and unmet medical needs for treating patients with high-risk pediatric neuroblastoma and other solid tumors. Drs. Modak, Kramer, and Mora will be available to answer questions at the conclusion of the event.

Y-mAbs management will also provide an in-depth overview of the Company’s broad and advanced product pipeline as well as a review of recent corporate and clinical developments. Y-mAbs is advancing two pivotal-stage product candidates, naxitamab and omburtamab, targeting tumors that express GD2 and B7-H3, respectively.

Members of the media and public may access the event via a live webcast.

OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium

On December 5, 2019 OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported it will present interim efficacy, immunological and safety data from its ongoing KEYNOTE-890 study of TAVO in combination with KEYTRUDA in patients with late-stage, heavily pretreated, chemo-refractory metastatic triple negative breast cancer (mTNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held December 10-14, 2019 (Press release, OncoSec Medical, DEC 5, 2019, View Source [SID1234551971]).

The poster, titled "Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) (KEYNOTE- 890/OMS-I141)," will be presented by lead author Melinda L. Telli, MD on Thursday, December 12th from 5:00 p.m. – 7:00 p.m. CST.

The SABCS abstracts are listed on the conference website under Abstracts at View Source!/7946 .

Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event

On December 5, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that Mr. Jed Latkin, Chief Executive Officer, will present at the 12th Annual LD Micro Main Event investor conference (Press release, Navidea Biopharmaceuticals, DEC 5, 2019, View Source [SID1234551967]). The conference will be held at the Luxe Bel Air Hotel in Los Angeles, CA on December 10-12, 2019. Mr. Latkin will present on Wednesday, December 11 at 10:20 a.m. PT (1:20 p.m. ET) in Track 4, which will be webcast.

Details of Navidea’s presentation are below. For those who wish to listen to the live webcast, please use the following link: View Source." target="_blank" title="View Source." rel="nofollow">View Source The webcast will be archived on Navidea’s investor relations website, View Source for 90 days following the live presentation.

Event:

12th Annual LD Micro Main Event

Date:

Wednesday, December 11, 2019

Time:

10:20 a.m. PT (1:20 p.m. ET)

Location:

Luxe Sunset Boulevard Hotel, Los Angeles, CA – Track 4

Webcast:

View Source

The 12th Annual LD Micro Main Event will feature 275 emerging growth companies and is expected to attract 1,500 attendees. To schedule a one-on-one meeting with Mr. Latkin, please contact Adam Holdsworth at [email protected].

Incyte to Present at Upcoming Investor Conference

On December 5, 2019 Incyte Corporation (Nasdaq:INCY) reported that it will present at the J. P. Morgan 38th Annual Healthcare Conference on Monday, January 13, 2020 at 8:30 am (PST) in San Francisco (Press release, Incyte, DEC 5, 2019, View Source [SID1234551966]).

The presentation will be webcast live and can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Employees in Genmab

On December 5, 2019 Genmab A/S (Nasdaq: GMAB) reported that at a board meeting the board decided to grant 83,658 restricted stock units to members of the board of directors, two members of management and employees of the company as well as the company’s subsidiaries and 195,011 warrants to employees of the company and the company’s subsidiaries (Press release, Genmab, DEC 5, 2019, View Source [SID1234551965]).

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the two members of management will be subject to forward looking performance criteria. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,615.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,615. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 458.61

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.